10329-98-3

Usage

Uses

Used in Pharmaceutical Industry:
1-NAPHTHYL-N-ACETYL-BETA-D-GLUCOSAMINIDE is used as a pharmaceutical compound for its potential therapeutic applications. The presence of the 1-naphthyl group may allow for specific interactions with biological targets, making it a candidate for the development of new drugs or drug delivery systems.
Used in Chemical Research:
1-NAPHTHYL-N-ACETYL-BETA-D-GLUCOSAMINIDE can be used as a research tool in the field of chemistry, particularly in the study of carbohydrate chemistry and the development of new synthetic methods for the preparation of complex carbohydrate derivatives.
Used in Material Science:
The unique structure of 1-NAPHTHYL-N-ACETYL-BETA-D-GLUCOSAMINIDE may also find applications in material science, where it could be used to develop new materials with specific properties, such as improved biocompatibility or enhanced interaction with biological systems.

Upstream product

• 121356-12-5 [1]naphthyl-(tri-O-acetyl-2-acetylamino-2-deoxy-β-D-glucopyranoside) 
• 3006-60-8 Acetic acid (2R,3R,4R,5S,6R)-2,5-diacetoxy-6-acetoxymethyl-3-acetylamino-tetrahydro-pyran-4-yl ester 
• 3006-60-8 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranose 
• 10034-19-2 1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-α-D-glucopyranose hydrochloride 
• 3006-60-8 2-acetamido-3,4,6-tri-O-acetyl-D-glucopyranosyl acetate 
• 90-15-3 α-naphthol 
• 3068-34-6 Acetic acid (2R,3S,4R,5R,6R)-3-acetoxy-2-acetoxymethyl-5-acetylamino-6-chloro-tetrahydro-pyran-4-yl ester 

Relevant academic research and scientific papers

Acceptor substrate-based selective inhibition of galactosyltransferases

This paper describes the discovery of glycosyl acceptor analogs as potent and selective inhibitors of α-1,3- and β-1,4- galactosyltransferases. Incorporation of an appropriate aromatic group to the aglycon position of the enzyme's acceptors results in a strong inhibition, representing the first and most potent small uncharged molecules as selective inhibitors of these two enzymes and thus providing a new strategy for the development of selective glycosyltransferase inhibitors.

Design of N-acetyl-6-sulfo-β-D-glucosaminide-based inhibitors of influenza virus sialidase

Biological activity of N-acetyl-6-sulfo-β-D-glucosaminides (6-sulfo-GlcNAc 1) having a structural homology to N-acetylneuraminic acid (Neu5Ac 2) and 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5Ac2en 3) was examined in terms of inhibitory activity against influenza virus sialidase (influenza, A/Memphis/1/71 H3N2). pNP 6-Sulfo-GlcNAc 1a was proved to show substantial activity to inhibit the virus sialidase (IC50=2.8 mM), though p-nitrophenyl (pNP) GlcNAc without 6-sulfo group and pNP 6-sulfo-GlcNH3+ 1b without 2-NHAc showed little activity (IC50 >50 mM). The activity was enhanced nearly 100-fold when the pNP group of 1a was converted to p-acetamidophenyl one 5 (IC50=30 μM) or replaced with 1-naphthyl 6 (IC50=10 μM) or n-propyl one 8 (IC50=11 μM).